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Lyme disease is caused by genetically divergent spirochetes, including 3 pathogenic geno-
species: Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii. Serodiagnosis is complicated
by this genetic diversity. A synthetic peptide (C6), based on the 26-mer invariable region (IR6)
of the variable surface antigen of B. burgdorferi (VlsE), was used as ELISA antigen, to test
serum samples collected from mice experimentally infected with the 3 genospecies and from
European patients with Lyme disease. Regardless of the infecting strains, mice produced a
strong antibody response to C6, which indicates that IR6 is antigenically conserved among
the pathogenic genospecies. Twenty of 23 patients with culture-confirmed erythema migrans
had a detectable antibody response to C6. A sensitivity of 95.2% was achieved, with serum
samples collected from patients with well-defined acrodermatitis chronica atrophicans. Four-
teen of 20 patients with symptoms of late Lyme disease also had a positive anti-IR6 ELISA.
Thus, it is possible that C6 may be used to serodiagnose Lyme disease universally.
Lyme borreliosis is the most prevalent tick-borne disease in
Europe, the United States, and parts of Asia [1–4]. It is a com-
plex multisystem disorder with early manifestations, such as
erythema migrans (EM), acute meningitis or meningopolyneu-
ritis and acute arthritis, and late signs and symptoms that in-
clude chronic arthritis, chronic neurologic abnormalities, and
acrodermatitis chronica atrophicans (ACA) [5–7].
Lyme disease is caused by a group of genetically diverse
spirochetes collectively termed Borrelia burgdorferi sensu lato.
This complex includes several genospecies, of which 3 are
known to be pathogenic to humans. They are B. burgdorferi
sensu stricto, B. garinii, and B. afzelii [8, 9]. Thus far, all the
North American pathogenic strains that have been identified
are B. burgdorferi sensu stricto [9]. In contrast, in Europe [8,
9] and China [4], all 3 genospecies are found, with B. garinii
and B. afzelii being the most prevalent isolates. Clinical and
pathological manifestations of Lyme disease vary geographi-
cally, according to which is the predominant infectious geno-
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species. Borrelial lymphocytoma, ACA, and encephalomyelitis
are found mainly in Europe, whereas disseminated early infec-
tion, secondary EM, and arthritis are more common in the
United States [10–13].
Although it is recommended that Lyme disease diagnosis be
based on the patient’s clinical history (including symptoms and
exposure to the tick vector), physical findings, and laboratory
data other than serology [14], serologic tests are used widely as
confirmatory. ELISA and immunoblotting are the techniques
most commonly used for Lyme disease serology, both in Europe
and in the United States. In the United States, the Centers for
Disease Control and Prevention (CDC) have recommended a
2-tiered diagnostic approach. This entails an initial ELISA of
relatively high sensitivity but low specificity followed, when
positive, by an immunoblot [15]. Several advantages are as-
sociated with this approach, such as enhanced specificity and
the opportunity to estimate duration of infection. The need to
include the immunoblotting technique, however, will increase
the cost of Lyme disease diagnosis and probably will further
enhance inter- and intralaboratory discrepancies, because the
test is itself more difficult to perform than a standard ELISA,
and because its outcome may depend on subjective interpre-
tation of the banding pattern.
There is evidence indicating that antigens prepared from dif-
ferent B. burgdorferi strains and genospecies influence reactivity
with human antibody, both in ELISA and in immunoblot as-
says. A single serum sample or a serum pool from patients with
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Lyme disease shows remarkably different banding patterns on
immunoblots that are prepared with antigens from different
strains of B. burgdorferi sensu lato [16–19]. ELISA antigens
prepared from different spirochete strains also significantly in-
fluence antibody titers of human serum [20, 21]. Because of
these reasons and because the infecting strain or genospecies
is usually unknown [17], serodiagnosis of Lyme disease is even
more problematic in Europe than in the United States [17–20].
This difficulty is compounded by the fact that subclinical in-
fections are common in Europe; thus, serodiagnosis is often
used in lieu of clinical diagnosis [22, 23]. A simple, sensitive,
and specific test that is applicable, regardless of the infecting
strain, is urgently needed in Europe.
The variable surface antigen of B. burgdorferi, VlsE, contains
a 26-mer invariable region (IR6) [24]. The IR6 sequence remains
unchanged during antigenic variation [25] and, on the basis of
the data available thus far, is conserved among 3 strains of 2
genospecies of B. burgdorferi sensu lato [24]. IR6 is highly im-
munogenic. Experimental infections of monkeys and mice elicit
in all the infected animals an early, strong, and persistent an-
tibody response to a peptide (C6) that reproduces the IR6 se-
quence [24, 26]. This same peptide, when used in a diagnostic
ELISA, detects antibody in serum samples from US patients
with early Lyme disease with a sensitivity of 85% and a sen-
sitivity <100% in patients with chronic disease, with a specificity
of 99% [26]. In the current study, serum samples from mice
experimentally infected with European strains of B. burgdorferi
sensu lato were used to evaluate antigenic conservation of IR6.
In addition, human serum samples from European patients with
either early or late Lyme disease were tested, to assess sensitivity
of the C6 peptide ELISA in a European setting.
Materials and Methods
Spirochete strains, ticks, mice, and mouse infection protocol.
Female BALB/c mice (6–8 weeks old) were infected by subcuta-
neous needle inoculation with 105 spirochetes of B. garinii strains
Pbi, Pohm, or B. burgdorferi sensu stricto strain B31 or by tick
bite. Before needle inoculation, spirochetes were cultured in BSK-
II medium, which was supplemented with 10% rabbit serum (Sigma
Chemical, St. Louis). Nymphal Ixodes ricinus were field collected
in Malonne, Belgium, and Neuchaˆtel, Switzerland, by flagging veg-
etation. Infection rates were 33% (7/21) for ticks from Neuchaˆtel,
as assessed by immunofluorescence and Borrelia isolation, and 20%
(9/45) for ticks from Malonne, as assessed by polymerase chain
reaction (PCR). Eleven (Neuchaˆtel origin) or 15 (Malonne origin)
ticks were applied to hollow plastic caps placed on the back of
each mouse. B. burgdorferi infection by tick bite was confirmed by
ear punch–biopsy culture and/or xenodiagnosis. Immunofluoresc-
ence, PCR, spirochete isolation, ear punch–biopsy culture, and
xenodiagnosis were performed as described elsewhere [27, 28]. In-
fecting strains were classified into genospecies on the basis of a
standard protocol described elsewhere [8]. Blood samples were
drawn at 4 weeks after inoculation via needle or tick bite.
Spirochete isolation from patients with EM and genospecies clas-
sification. Skin punch biopsies were taken from the erythematous
border of the EM lesions after local anesthesia and were cultured
at 347C in BSK-II medium supplemented with 10% rabbit serum.
Cultured fluid was monitored weekly for the presence of spirochetes
under a darkfield microscope for 1 month. Grown spirochetes were
classified into genospecies on the basis of procedure and standards
described elsewhere [8].
Human Lyme disease serum sources. Two sources of human se-
rum were used in this study, one from Austria and the other from
Italy. Two serum panels were obtained from each source, one from
patients with early Lyme disease and the other from patients with
late disease manifestations. The early serum panel from Austria con-
sisted of 29 specimens collected from 11 patients with EM. Two or
3 specimens were serially collected from each patient. Skin biopsies
from all but 1 of the Austrian patients were cultured. All the 10
cultured biopsies were positive for B. burgdorferi. The late serum
panel from this source consisted of 21 specimens from 21 IgG-se-
ropositive patients with clinically and histologically diagnosed ACA.
The Italian panel of early serum specimens consisted of 20 samples
collected from 13 patients with EM with culture-confirmed B. burg-
dorferi infection. As many as 2 samples per patient were serially
collected. Chronic serum specimens from Italy were from 20 patients
with clinically diagnosed signs and symptoms that were consistent
with late neuroborreliosis, arthritis, or ACA and contained antibody
to B. burgdorferi, as detected by ELISA [29]. Early specimens were
collected serially, starting at disease onset and continuing thereafter
for 3 months, during and after antibiotic treatment.
Control serum specimens. Control serum specimens were col-
lected randomly from hospital patients in 2 areas of the world where
Lyme disease is not endemic, Louisiana ( ) and Sicily, Italyn p 20
( ).n p 21
ELISA diagnosis. A commercial ELISA kit (DAKOPATTS
A/S, Copenhagen, Denmark) was used to test the serum specimens
from Austrian patients with early and late Lyme disease, according
to the manufacturer’s instructions. The antigen was native flagellar
protein purified from cultured B. afzelii strain DK-1.
Immunoblot diagnosis. A commercial immunoblot assay kit
(MRL Diagnostics, Cypress, CA) was employed to analyze the
Austrian serum panel obtained from patients with early Lyme dis-
ease, according to the manufacturer’s recommendations. The anti-
gen consisted of whole-cell sonicates of cultured B. garinii strain
20047. A test was considered to be positive when >1 of the 23- or
39-kDa IgM bands or 4 of the 21-, 23-, 37-, 39-, 41-, 45-, or 93-
kDa IgG bands were visible on the immunoblots.
To analyze serum specimens from the early Lyme disease Italian
patients with increased sensitivity, 3 local strains—B. garinii BITS,
B. afzelii BL3, and B. burgdorferi sensu stricto Alcaide—were in-
dividually used as a source of immunoblot antigens. The anti–B.
burgdorferi antibodies were probed with goat anti–human IgG or
IgM as secondary antibodies. Diagnosis was made on the basis of
criteria described elsewhere [18, 29].
Peptide and biotinylated peptide preparation. A 26-mer peptide
(C6 [CMKKDDQIAAAMVLRGMAKDGQFALK]), which repro-
duced the IR6 sequence of VlsE cloned from B. garinii strain IP90,
was synthesized and conjugated to biotin, as described elsewhere [24].
C6-peptide–based ELISA. The C6-peptide–based ELISA was
performed as described elsewhere [24]. Ninety-six–well ELISA plates
were coated with 100 mL per well of 4 mg/mL streptavidin (Pierce
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Figure 1. Antigenic conservation of a 26–amino acid invariable region (IR6) of the variable surface antigen of Borrelia burgdorferi (VlsE)
among pathogenic B. burgdorferi genospecies. Mice were infected with European B. burgdorferi sensu lato strains by tick bite (A and B) or by
needle inoculation (C). Ticks were field collected in Belgium (A) and Switzerland (B). Blood samples were drawn at 4 weeks after inoculation.
Antibody response to IR6 was assessed with the C6 ELISA. Cutoff value (0.171) was based on the mean ELISA optical density (OD) plus 3 SD
of serum samples collected from 35 uninfected mice. Sixteen of the 19 animals in A were infected, as confirmed by ear punch–biopsy culture, but
the infecting strains were not classified. Mice 60, 70, and 72 were not infected. All but 2 of the mice in B (mice 55 and 61) were infected, as
determined by ear punch–biopsy culture and/or xenodiagnosis. Infecting strains were classified into genospecies. Mice 67 and 75 were positive
by xenodiagnosis only. Infecting strains were not identified. Mouse 59 was infected with a B. garinii strain. Remaining mice were infected with
B. afzelii strains. In C, animals were infected with B. garinii strains PBi (mice 4, 15, and 26) or Pohm (mice 5, 16, and 27) or B. burgdorferi sensu
stricto strain B31 (mice 1, 12, and 23) by needle inoculation.
Chemical, Rockford, IL) in coating buffer and were incubated at
47C overnight. The remaining steps were conducted in a rotatory
shaker at room temperature. After 2 3-min washes with 200 mL per
well of PBS/T at 200 rpm, 200 mL of 5 mg/mL biotinylated peptide
dissolved in blocking solution (PBS/T supplemented with 5% nonfat
dry milk) was applied to each well. The plate was shaken at 150 rpm
for 2 h. After 3 washes with PBS/T, as described above, 50 mL of
mouse or human serum, diluted 1:200 with blocking solution, was
added to each well. The plate was incubated at 150 rpm for 1 h and
then washed 3 times with PBS/T. Each well then received 100 mL of
0.5 mg/mL goat anti–mouse IgG (heavy and light-chain specific;
Sigma) or 0.1 mg/mL of anti–human IgG (heavy- and light-chain
specific; Pierce Chemical), each conjugated to horseradish peroxidase
and dissolved in blocking solution. The plate was incubated for 1 h
while shaking. After 4 washes with PBS/T, each for 3–6 min, the
antigen-antibody reaction was probed using the TMB Microwell Per-
oxidase Substrate System (Kirkegaard and Perry Laboratories,
Gaithersburg, MD), and color was allowed to develop for 10 min.
The enzyme reaction was stopped by the addition of 100 mL of 1 M
H3PO4. Optical density was measured at 450 nm.
Results
Antigenic conservation of IR6 among 3 pathogenic B. burgdor-
feri genospecies. Although the IR6 amino acid sequence is con-
served among strains and genospecies of B. burgdorferi sensu
lato, as shown with sequence data from 3 strains of 2 genospecies,
B. burgdorferi sensu stricto and B. garinii [24], a single amino
acid substitution may destroy an epitope or diminish antibody-
binding affinity. Moreover, no VlsE sequence data are available
from B. afzelii strains. To address these issues in relation to the
diagnostic potential of the C6 ELISA, we conducted extensive
experimental infection studies with different B. burgdorferi
strains. Previously, 10 rhesus monkeys and 13 mice were exper-
imentally infected by tick or needle inoculation with B. burg-
dorferi sensu stricto strains B31, JD1, or Sh-2-82; all the animals
produced an early and persistent antibody response to IR6 [24,
26].
In the current study, the anti–C6 antibody response elicited by
European spirochetal strains was investigated in experimentally
infected mice. Two sets of mice were infected by tick bite. The
ticks were field collected in 2 European countries where both B.
garinii and B. afzelii are endemic. The first set ( ) wasn p 19
inoculated with ticks collected in Belgium, and the second set
( ) was inoculated with ticks from Switzerland. Sixteenn p 18
mice from the first set were infected, as demonstrated by ear
punch–biopsy culture, and 16 from the second set were also in-
fected, as assessed by ear punch–biopsy culture and/or xenodi-
agnosis. All the mice that proved to be infected by culture and/
or xenodiagnosis produced a strong antibody response to C6,
whereas mice negative by the former criteria were C6-antibody
negative (figure 1A and 1B). Fourteen mice from the second set
were culture positive, whereas mice 67 and 75 of this set were
positive by xenodiagnosis. Speciation was performed only with
the 14 isolates cultivated from the second set. Thirteen of these
mice were infected with B. afzelii strains. Mouse 59 was infected
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with B. garinii. The infecting strains isolated by xenodiagnosis
were not identified.
Although almost the entire second group of mice (inoculated
with ticks from Switzerland) was infected with B. afzelii strains,
it is possible that the infecting strains in some mice of the first
set were B. garinii, because the ticks that were used in this case
were collected in Belgium. In light of the fact that the sequence
of the diagnostic probe C6 used in this study was part of VlsE
from B. garinii strain IP90 [24], it is reasonable to assume that
antibodies elicited during infections with B. garinii strains should
react with C6. To demonstrate the antigenic conservation of IR6
among B. garinii strains, however, we experimentally infected 6
mice with B. garinii strains other than IP90—namely, Pbi or
Pohm, by needle inoculation. B. burgdorferi sensu stricto strain
B31 was used as a control. Infection in these mice was not as-
sessed by culture or xenodiagnosis. Antibody to C6 was found
in mice, regardless of the inoculated strains (figure 1C). These
results further confirmed the antigenic conservation of IR6.
Sensitivity of the C6 ELISA in patients with early Lyme dis-
ease. Twenty of 23 patients with culture-confirmed EM (87%)
had a detectable anti–IR6 antibody response (figure 2). One
patient (A3) with positive EM was C6 ELISA negative (figure
2). No culture was performed with this patient. Results ob-
tained with commercially available immunoblot and ELISA
kits show that the C6 ELISA detected more positive results
than did any of these tests, used either alone or combined (figure
2, Austrian panel). The C6 ELISA also performed, in terms of
diagnostic sensitivity, better than any of the 3 antigen prepa-
rations that were used to diagnose the Italian serum panel (fig-
ure 2, Italian panel). Bacterial isolation and classification re-
vealed that the patients were infected with either B. garinii or
B. afzelii strains (figure 2). This result provided additional evi-
dence that IR6 is antigenically conserved across the genospecies
barriers of the B. burgdorferi sensu lato complex.
Sensitivity of the C6 ELISA for serodiagnosing late Lyme dis-
ease. Twenty (95%) of 21 Austrian patients with histologically
confirmed ACA and positive IgG serology with commercially
available tests showed a strong antibody response to IR6 (figure
3). A sensitivity of 70% (14/20) was obtained when a panel of
serum samples from Italian patients with signs and/or symp-
toms consistent with late Lyme disease was tested. These 14
positive results included 3 of 4 patients with late arthritis, 8 of
12 with late neurologic manifestations, and 3 of 4 with ACA,
which indicate that the C6 ELISA was able to detect different
manifestations that might be caused by various B. burgdorferi
strains. It should be pointed out, however, that clinical diag-
nosis of late Lyme disease can be difficult because of the absence
of well-defined clinical criteria, especially in the case of neuro-
logic manifestations.
Specificity of the C6 ELISA. We previously assessed diag-
nostic specificity of the C6 ELISA with an array of 77 serum
samples from patients with other spirochetal infections or auto-
immune or neurologic diseases [26]. To extend this survey, we
assayed 21 serum specimens collected from a European non-
endemic area. No detectable antibody response to C6 was noted
(data not shown).
Discussion
Serodiagnosis of Lyme disease is hampered, in part, by poly-
morphism of antigenic proteins of B. burgdorferi. In Europe,
this problem is more serious, because all 3 of the pathogenic
genospecies are prevalent. In previous studies, we showed that
experimental infections of monkeys and mice with B. burgdor-
feri sensu stricto strains B31, JD1, or Sh-2-82 elicited an early,
strong, and persistent antibody response to IR6 [24, 26]. All
these strains had been isolated in the United States. In addition,
human serum samples collected from American patients with
Lyme disease yielded sensitivities of 85% (117/138) and 100%
(59/59) for early and late Lyme disease, respectively, when as-
sayed with the C6 ELISA [26]. In the present study, European
strains were investigated. Mice responded strongly to IR6, re-
gardless of whether they were infected with B. garinii or B.
afzelii strains by tick or needle inoculation. In humans, sensi-
tivities of 83% (20/24) and 95% (20/21) were obtained from
European patients with clinically well defined, early (EM, cul-
ture confirmed) and late (histologically confirmed) Lyme dis-
ease (ACA), respectively (figures 2 and 3). Several independent
groups have noted that European patients show restricted anti-
body responses to B. burgdorferi antigens, which, in part, con-
tributes to the relatively lower sensitivity in European serodi-
agnosis [17–20]. This difference was not apparent when the C6
ELISA was used, because similar diagnostic sensitivities were
obtained with North American [24, 26] and European serum
samples (figures 2 and 3). The exception was the panel of serum
samples collected from Italian patients with chronic symptoms,
in which the C6 ELISA yielded a sensitivity of only 70% (figure
3). Clinical diagnosis of late Lyme disease, however, is com-
pounded by the absence of pathognomonic signs and the virtual
impossibility of confirming diagnosis by culture. Our current
and previous studies [24, 26] thus demonstrate that the VlsE
immunodominant IR6 is antigenically conserved among the 3
B. burgdorferi genospecies and thus potentially can serve as a
universal probe for the serodiagnosis of Lyme disease.
Antigenic conservation is different from molecular (or se-
quence) conservation, because a single amino acid substitution
may destroy antigenic reactivity of an epitope but does not
significantly alter sequence conservation. On the other hand, a
peptide with even extensive amino acid substitutions may still
retain antigenic reactivity of a particular epitope. Although
limited molecular data from 3 strains of 2 genospecies of B.
burgdorferi sensu lato indicate that the IR6 sequence is con-
served [24, 25], it is unknown whether VlsE is universally ex-
pressed by all pathogenic B. burgdorferi strains during a mam-
malian infection. To address these issues, 37 mice were infected
by tick bite with European isolates. Field-caught ticks may
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Figure 2. Sensitivity of the C6 ELISA for diagnosing early Lyme disease. Two panels of human serum specimens of Austrian (top panel) or
Italian (bottom panel) origin were tested with the C6 ELISA. Cutoff value (0.380) was based on the mean ELISA optical density (OD) plus 3 SD
of 20 human serum samples collected from hospitalized patients in an area nonendemic for Lyme disease in the United States. Except for serum
A3 from a patient with erythema migrans (EM), for whom spirochetal culture was not performed, all the serum samples were collected from
patients with culture-confirmed EM. Blood samples were collected from each patient at 1–3 time points after disease onset. For the Austrian
panel, samples were collected before treatment (pretreatment), and at 1 (posttreatment I) and 3 months (posttreatment III) after antibiotic treatment.
For the Italian panel, blood was collected at 1 (posttreatment I), 2 (posttreatment II), and 3 (posttreatment III) months after treatment. All the
patients received antibiotic treatment. In some cases, not all 3 serial samples were available for this study. Spirochete isolation and classification,
ELISA, and immunoblotting were performed, as described in Materials and Methods. For the Italian panel, 3 immunoblot antigens were prepared
from Borrelia garinii strain BITS, B. afzelii strain BL3, and B. burgdorferi sensu stricto strain Alcaide, respectively. Ba, B. afzelii; Bg, B. garinii;
ND, not performed; 2, negative ELISA or immunoblot diagnosis. Letters “a,” “b,” and “c” indicate positive IgM, IgG, or both IgM and IgG
serodiagnosis, respectively, by the method indicated.
harbor multiple spirochetal strains. Therefore, the infecting
strains could represent a broad spectrum of European B. burg-
dorferi sensu lato strains. Only the mice whose infection was
confirmed by ear punch–biopsy culture and/or xenodiagnosis
responded strongly to IR6, which indicates that VlsE is generally
expressed by, and that IR6 is antigenically conserved among,
European strains. Some of the mice might have been coinfected
with multiple strains, because the infecting spirochetes were
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Figure 3. Sensitivity of the C6 ELISA for diagnosing late Lyme
disease. Two panels of human serum specimens of Austrian (left panel)
or Italian (right panel) origin were tested with the C6 ELISA. Cutoff
value was defined as described in the legend to figure 2. The Austrian
serum panel was collected from patients with clinically diagnosed, his-
tologically confirmed acrodermatitis chronica atrophicans (ACA). The
Italian serum panel was collected from patients with clinically diag-
nosed late arthritis, late neurologic manifestations, or ACA. OD, op-
tical density.
classified at only the genospecies level in this study. None of
the 14 mice in the second set whose infection was confirmed
by culture appeared to be coinfected with multiple genospecies,
although it is formally possible, but unlikely, that certain in-
fectious isolates may not have been cultivable.
Mice are readily infected by needle inoculation with B. burg-
dorferi spirochetes. This form of infection does not, however,
fully mimic a natural infection. B. burgdorferi is naturally main-
tained in enzootic cycles that involve Ixodes ticks and vertebrate
hosts. The spirochete alters its pattern of protein expression
during these cycles. One typical example is the switch of outer
surface protein (Osp) A and OspC expression [30–32]. The or-
ganism makes or residually expresses OspA, but not OspC, in
the midgut of unfed ticks. The feeding process induces OspC
expression and either turns off or attenuates OspA expression.
This may be one of the reasons why anti–OspA antibody is
rarely detectable in early infection by tick bite [33, 34]. In con-
trast, OspA is abundantly expressed in cultured spirochetes,
and needle inoculation induces a strong early anti-OspA re-
sponse [33, 34]. Therefore, infection by tick bite was evaluated
first. Although VlsE expression in the tick, mammalian hosts,
and in vitro culture has not been studied extensively, the data
from our previous and current studies strongly indicate that
this lipoprotein is consistently expressed during an infection in
humans, monkeys, or mice, because anti–IR6 antibody is readily
detectable in acute and chronic infections in these hosts [24,
26]. This is one of the essential features that a diagnostic antigen
should possess.
In addition to the problems posed by antigenic polymorphism,
serodiagnosis of Lyme disease is further hampered by the low
specificity of the existing assays. This may be caused by cross-
reactive antigens shared among B. burgdorferi and other patho-
genic or nonpathogenic bacteria. Among these antigens are hom-
ologues of the omnipresent bacterial heat-shock proteins [35],
flagellin, which is shared with other spirochetes, such as B. hermsii
and Treponema pallidum [36], and a 60-kDa antigen that is ex-
pressed by a wide range of bacteria [37]. Other bacterial infections
may thus elicit antibodies that react with B. burgdorferi antigens,
causing false-positive results. In contrast to conventional diag-
nostic techniques, the C6 ELISA is highly specific. None of the
77 serum samples from patients infected with B. hermsii, the
spirochete that causes relapsing fever, or T. pallidum, the agent
of syphilis, or suffering from other chronic infections or diseases,
such as tuberculosis and multiple sclerosis, contained detectable
antibody to C6 [26]. Moreover, except for B. burgdorferi VlsE,
no other protein sequences homologous to IR6 could be identified
by BLAST searches in the National Center for Biotechnology
Information [24]. This high specificity was further confirmed by
our current data obtained with control European serum samples.
None of the 21 serum specimens collected from a European no-
nendemic area contained detectable antibody to IR6.
We compared the performance of the C6 ELISA with existing
ELISAs and immunoblot assays. For clinically and micro-
biologically confirmed acute cases (EM plus culture), the C6
ELISA was better than, or similar to, conventional ELISA and
immunoblot assays. For well-defined chronic cases (clinical di-
agnosis of ACA supported histologically), both C6 and con-
ventional ELISAs performed equally well. For less well-defined
chronic illness (clinical diagnosis of nonpathognomonic symp-
toms only), the C6 ELISA yielded a lower sensitivity than a
conventional ELISA. This might have resulted from the low
specificity of this ELISA. More chronic cases need to be studied
by us, to sort out the possible cause of this difference. Studies
conducted by several independent groups, however, indicate
that inter- or even intralaboratory variation in Lyme disease
diagnosis, using commercially available serological methods, is
frequently observed [38–40] and that the performances of such
tests differ dramatically from one another [41]. This makes any
comparisons of serologic data difficult to interpret.
Recently, the initiation of Lyme disease immunoprophylaxis
in humans through the use of the OspA vaccine has made
obsolete those diagnostic assays based on whole-cell antigens,
because these preparations include OspA. Predictably, the C6
ELISA does not detect anti–OspA antibodies [26]. Hence, ap-
proval and use of the OspA vaccine in Europe will not affect
the performance of our test.
Finally, perhaps the most compelling advantage of the C6
ELISA is its simplicity in terms of antigen preparation and
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assay utilization. A 26-mer peptide is easy and inexpensive to
synthesize. In terms of diagnostic utilization, <100 bands may
be counted on B. burgdorferi whole-cell immunoblots that are
reacted with Lyme disease patient serum samples, making it
often difficult to identify bands that are diagnostic markers [42].
Antigenic polymorphism is part of the problem. For example,
the Bdr antigen family is generally expressed by spirochetes of
the genus Borrelia, including the B. burgdorferi sensu lato spe-
cies, B. hermsii, B. turicatae, and B. parkeri [43]. The Bdr family
contains a large number of members that share antigenic de-
terminants and range in molecular weight from 10.7 to 38.5
kDa on immunoblots. A single B. burgdorferi sensu stricto iso-
late (strain B31) carries 17 distinct bdr alleles. Because of an-
tigenic cross-reactivity, antiserum to a single Bdr member re-
veals multiple bands on an immunoblot [43]. This problem is
even more complicated in Europe, where multiple criteria for
immunoblot diagnosis have to be adopted [18, 19]. In contrast,
the C6 ELISA depends on a single antigen, and the test’s format
may be adapted to yield a strictly quantitative readout or a
more rapid type with a semiquantitative readout. The antigenic
conservation of IR6 that we demonstrate here and the results
of our initial assessment of sensitivity and specificity augur well
for the successful use of C6-based diagnostic tests in Europe.
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